Advisors Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Advisors Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-61,738	Closed	-$645K	–	1493
2022 Q3	$645K	Sell	61,738 -1,552	-2%	-$17.3K	0.01%	868
2022 Q2	$680K	Sell	63,290 -13,194	-17%	-$109K	0.01%	871
2022 Q1	$724K	Sell	76,484 -4,997	-6%	-$46.9K	0.01%	895
2021 Q4	$941K	Sell	81,481 -1,345	-2%	-$15K	0.01%	844
2021 Q3	$791K	Sell	82,826 -500	-0.6%	-$5.12K	0.01%	891
2021 Q2	$803K	Buy	83,326 +4,574	+6%	+$44.6K	0.01%	894
2021 Q1	$778K	Buy	78,752 +33,181	+73%	+$514K	0.01%	902
2020 Q4	$1.05M	Buy	45,571 +30,874	+210%	+$631K	0.02%	764
2020 Q3	$208K	Buy	14,697 +6,808	+86%	+$99.2K	﹤0.01%	1171
2020 Q2	$119K	Buy	+7,889	New	+$96.1K	﹤0.01%	1266

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Advisors Asset Management's FOLD Position: Q4 2022 in Review

Advisors Asset Management sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 61,738 shares — an estimated $645K sold.

Advisors Asset Management first reported a position in FOLD in Q2 2020 and held it in 10 quarters. The position peaked at $1.05M in Q4 2020. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

Advisors Asset Management reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
Advisors Asset Management sold 61,738 Amicus Therapeutics shares in Q4 2022, an estimated $645K.
Advisors Asset Management first reported a position in Amicus Therapeutics in Q2 2020 and held it in 10 quarters.
Advisors Asset Management's Amicus Therapeutics position peaked at $1.05M in Q4 2020.
230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Advisors Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.